TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19809305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of XIIaA and BNP
Study: 19811637
Drug: AS1402 (1-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1402 (1-16 mg/kg) administered via intravenous infusion every 1 to 3 weeks until disease progression.
Study: 19811637
Drug: AS1402 (1-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1402 (1-16 mg/kg) administered via intravenous infusion.
Study: 19812383
Drug: Busulfan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation
Study: 19812461
Drug: Memantine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine at a target dose of 20 mg daily for 26 weeks
Study: 19817748
Drug: Vorinostat 100
Normalized name: vorinostat 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat 100 or 200 mg administered twice daily for 14 consecutive days followed by a 1-week rest interval.
Study: 19817748
Drug: Vorinostat 200
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 200 mg
Study: 19818257
Drug: High-dose ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ziprasidone
Study: 19820552
Drug: Escitalopram (ESC)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (ESC) plus bupropion (BUP), rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15
Study: 19829297
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg +/-20% s.c. b.i.d.)
Study: 19833304
Drug: Adenosine administered
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine administered by intravenous infusion (140 microg/kg/min) to obtain hyperemic flow profiles.
Study: 19835828
Drug: AS03(A)-adjuvanted A/Indonesia/5/2005
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted A/Indonesia/5/2005 vaccine (single booster dose)
Study: 19835828
Drug: AS03(A)-adjuvanted A/Vietnam/1194/2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier)
Study: 19835828
Drug: Non-adjuvanted A/Vietnam/1194/2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier, two booster doses)
Study: 19835828
Drug: Un-primed control
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Un-primed control group (two doses of adjuvanted vaccine)
Study: 19837930
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion at 0.25 pmol x kg(-1) x min(-1) on day 1 and day 3
Study: 19837930
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion on day 1 and day 3
Study: 19837930
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion in healthy controls on day 1
Study: 19838774
Drug: Rituximab therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab therapy with co-treatment
Study: 19843887
Drug: Lumiliximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiliximab (375 mg/m² or 500 mg/m²) combined with fludarabine, cyclophosphamide, and rituximab (FCR) for 6 cycles
Study: 19843899
Drug: Omega-3 acid
Normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 acid ethyl esters (2 g/d, containing 930 mg EPA and 750 mg DHA)
Study: 19843899
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil placebo capsules
Study: 19846066
Drug: TA-CD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-CD vaccine (82 microg, n = 4; 360 microg, n = 6) administered at weeks 1, 3, 5, and 9
Study: 19846066
Drug: Cocaine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0 mg, 25 mg, 50 mg)
Study: 19846730
Drug: LA volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA volume index >32 mL/m(2)
Study: 19850694
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone withdrawal (L-T4)
Study: 19852963
Drug: Des-gamma-carboxy prothrombin
Normalized name: Des-gamma-carboxy prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 40 mAU/mL
Study: 19852963
Drug: Des-gamma-carboxy prothrombin
Normalized name: Des-gamma-carboxy prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 150 mAU/mL
Study: 19852963
Drug: Alpha-fetoprotein (AFP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-fetoprotein (AFP) at month 0 with cutoff of 20 ng/mL
Study: 19852963
Drug: Alpha-fetoprotein (AFP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-fetoprotein (AFP) at month 0 with cutoff of 200 ng/mL
Study: 19852963
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DCP and AFP
Study: 19852963
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tests
Study: 19854499
Drug: AAV2-hRPE65v2 gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-hRPE65v2 gene therapy (1.5 x 10(10) vector genomes, 4.8 x 10(10) vector genomes, 1.5 x 10(11) vector genomes)
Study: 19854499
Drug: AAV2-hRPE65v2 gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-hRPE65v2 gene therapy
Study: 19856395
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication adherence (MedAd)
Study: 19856395
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence during dose titration
Study: 19858149
Drug: Maternal circulating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal circulating blood group antibodies
Study: 19858174
Drug: Nutritious, culturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritious, culturally appropriate daily meal (weeks 1-8) and food package (weeks 9-32) (n=137)
Study: 19858725
Drug: hs-CRP >or=2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP >or=2 mg/l in patients without prior CVD and LDL <3.4 mmol/l
Study: 19864401
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of fish (1-2 servings, 25-50 g/week)
Study: 19864401
Drug: <101 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: <101 g fish/week
Study: 19864401
Drug: >=101 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: >=101 g fish/week
Study: 19877976
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fluoxetine and Cognitive-Behavioral Therapy (COMB)
Study: 19877976
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) or Cognitive-Behavioral Therapy (CBT)
Study: 19882497
Drug: Oral corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroid use
Study: 19886987
Drug: Protracted 5FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted 5FU intravenous infusion (200 mg/m2 daily) plus LAR octreotide (20 mg monthly)
Study: 19888782
Drug: Triptorelin embonate
Normalized name: Triptorelin embonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin embonate (pamoate) 22.5 mg, two consecutive intramuscular injections at an interval of 24 weeks
Study: 19889129
Drug: Galantamine-ER 8-24
Normalized name: Galantamine Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine-ER 8-24 mg/day for 4 months
Study: 19889129
Drug: Galantamine-ER treatment
Normalized name: galantamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine-ER treatment
Study: 19889819
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg phytosterols/d
Study: 19889819
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg phytosterols/d
Study: 19889819
Drug: 59 mg
Normalized name: aspirin 259 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 59 mg phytosterols/d (control)
Study: 19889819
Drug: 459 mg
Normalized name: petrolatum 459 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 459 mg phytosterols/d
Study: 19890127
Drug: Synthetic peptide-based
Normalized name: Copolymer I (synthetic peptide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic peptide-based erythropoietin-receptor agonist (Hematide); administered subcutaneously at an initial dose of 0.05 mg/kg every 4 weeks
Study: 19890203
Drug: Lopinavir 400
Normalized name: LOPINAVIR 400MG/RITONAVIR 100MG/5ML SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir 400 mg and Ritonavir 100 mg, given twice daily for 4 weeks
Study: 19897179
Drug: Repeated-dose intravenous
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-dose intravenous ketamine (six infusions over 12 days)
Study: 19901191
Drug: Reconstituted high-density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted high-density lipoprotein (rHDL) infusion (CSL-111; 20 mg . kg(-1) . h(-1)) for 4 hours
Study: 19902266
Drug: Ibuprofen treatment
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen treatment for patent ductus arteriosus (PDA)
Study: 19902266
Drug: No ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No ibuprofen treatment
Study: 19902266
Drug: Ibuprofen treatment
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen treatment for PDA
Study: 19906082
Drug: Single intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of triamcinolone combined with bevacizumab
Study: 19906624
Drug: Tenofovir and
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir and emtricitabine once daily plus nevirapine twice daily
Study: 19909496
Drug: Progressive high-impact
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive high-impact training (high intensity levels > 3.9 g)
Study: 19909496
Drug: Progressive high-impact
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive high-impact training (first three months of exercise exceeding 1.1 g)
Study: 19915292
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of etidronate cyclically
Study: 19915292
Drug: High-dose glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoids (GCs)
Study: 19916705
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 (treatment-naïve subgroup)
Study: 19916705
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 (insulin +/- OADs subgroup)
Study: 19918104
Drug: Generic lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic lopinavir/ritonavir 200/50 mg tablet formulation (400/100 mg twice daily)
Study: 19918104
Drug: Kaletra(R) soft-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaletra(R) soft-gel capsules
Study: 19918104
Drug: Generic lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic lopinavir/ritonavir tablet
Study: 25758746
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg twice daily
Study: 19920819
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with metronomic etoposide (10 mg kg(-1) bevacizumab biweekly and 50 mg m(-2) etoposide daily for 21 consecutive days each month)
Study: 19923375
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg folate/d
Study: 19923475
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with isoniazid, gatifloxicin, levofloxacin, and moxifloxacin
Study: 19929182
Drug: Prescription redemption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription redemption for ACE inhibitor or angiotensin-II receptor antagonist
Study: 19930156
Drug: VEGFR2-169 peptide
Normalized name: Vegfr2-169 peptide vaccine
DrugBank: VEGFR2-169 (DB16152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGFR2-169 peptide vaccine combined with gemcitabine (1000 mg/m² on days 1, 8, and 15 in a 28-day cycle)
Study: 19930156
Drug: VEGFR2-169 peptide
Normalized name: Vegfr2-169 peptide vaccine
DrugBank: VEGFR2-169 (DB16152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGFR2-169 peptide vaccine combined with gemcitabine
Study: 19930156
Drug: VEGFR2-169 peptide
Normalized name: Vegfr2-169 peptide vaccine
DrugBank: VEGFR2-169 (DB16152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGFR2-169 peptide vaccine
Study: 19930599
Drug: Nedaplatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin (10 mg/body/day) and 5-FU (500 mg/body/day) with radiation (50.4-66 Gy)
Study: 19931137
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² IV and oxaliplatin 130 mg/m² IV every 21 days
Study: 19932054
Drug: GEMOX-B (bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX-B (bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2), oxaliplatin 85 mg/m(2))
Study: 19932729
Drug: 14.6 g
Normalized name: ZINC OXIDE 14.6 g in 100 g TOPICAL CREAM [Practical Alchemy Hydrating SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.6 g cis-9,trans-11 CLA and 4.7 g trans-10,cis-12 CLA isomers daily for 3 weeks
Study: 19933994
Drug: Metformin (1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,700 mg daily) plus folic acid (400 microg daily), n = 25
Study: 19936297
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% permethrin for scabies treatment and referral for pyoderma treatment according to guidelines.
Study: 19936297
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass scabies treatment with 5% permethrin cream offered to all community residents.
Study: 19946413
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg/day
Study: 19946413
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg/day
Study: 19946413
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg/day and 300 mg/day
Study: 19953376
Drug: Best possible
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best possible invasive therapy (endovascular, neurosurgical, and/or radiation therapy)
Study: 19955196
Drug: High-dose 9-cis-beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 9-cis-beta-carotene (four capsules daily for 90 days)
Study: 19962985
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin (264.3 +/- 25 mU/L)
Study: 19963351
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support (parenteral nutrition)
Study: 19965662
Drug: Fostamatinib disodium
Normalized name: fostamatinib disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib disodium 200 mg twice daily
Study: 19995432
Drug: Mismatch concept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mismatch concept in acute stroke treatment using perfusion imaging (PI) with a fixed dosage of 5 ml 1 M Gadobutrol.
Study: 19995432
Drug: Mismatch concept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mismatch concept in acute stroke treatment using perfusion imaging (PI).
Study: 19995444
Drug: NIR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR treatment to left forehead (F3)
Study: 19995444
Drug: NIR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR treatment to right forehead (F4)
Study: 19995444
Drug: NIR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR treatment (on condition)
Study: 19995444
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (light off)
Study: 19996412
Drug: Deferasirox (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (mean dose 32.6 mg/kg per day) in the cardiac iron reduction arm
Study: 20001658
Drug: Lipid-lowering drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drugs (LLD) for >3 months (stable medication >6 weeks)
Study: 20001658
Drug: Good treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good treatment adherence
Study: 20001856
Drug: Enfuvirtide-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide-containing therapy (including 2 reverse-transcriptase inhibitors and a ritonavir-boosted protease inhibitor) for at least 48 weeks
Study: 20003269
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin (400 mg bid)
Study: 20003832
Drug: Pegvisomant, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant, administered as daily subcutaneous injections adjusted according to IGF-I levels.
Study: 20007560
Drug: Nonmyeloablative transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by G-CSF, with 300 cGy total-body irradiation plus alemtuzumab before transplantation and sirolimus afterward
Study: 20007792
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in renal patients
Study: 20007792
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg(-1) in renal patients
Study: 20007792
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in healthy controls
Study: 20007792
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg(-1) in healthy controls
Study: 20007809
Drug: Intravenous PEG-asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PEG-asparaginase (2500 IU/m²) administered over 1 hour during remission induction
Study: 20008298
Drug: CEP-701 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-701 (80 mg orally twice daily)
Study: 20014952
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg valacyclovir oral suspension (single dose)
Study: 20014952
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg valacyclovir oral suspension (twice daily for 3-5 days)
Study: 20014952
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg valacyclovir oral suspension (3 times daily for 5 days)
Study: 20014952
Drug: Valacyclovir oral
Normalized name: valacyclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir oral suspension (various dosages)
Study: 20015886
Drug: escalated imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) combined with intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7)
Study: 20015886
Drug: escalated imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalated imatinib and intravenous cytarabine
Study: 20027045
Drug: High concentrations
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentrations of Atopobium vaginae (10^6/mL or more)
Study: 20027045
Drug: High concentrations
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentrations of Gardnerella vaginalis (10^7/mL or more)
Study: 20027045
Drug: High concentrations
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentrations of A vaginae and G vaginalis together
Study: 20027045
Drug: High vaginal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vaginal fluid concentrations of A vaginae and G vaginalis
Study: 20028332
Drug: Tat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat vaccine administered 5 times, every four weeks, subcutaneously (SC) with alum adjuvant or intradermically (ID) without adjuvant at doses of 7.5 microg, 15 microg, or 30 microg.
Study: 20028332
Drug: Tat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat vaccine (therapeutic immunization)
Study: 20032009
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed to smokers (60%)
Study: 20032009
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed to smokers
Study: 20036194
Drug: Figitumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (20 mg/kg)
Study: 20039404
Drug: Belimumab plus
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab plus standard of care therapy